Cargando…

Efficacy of Dapagliflozin in Southern Europe Across the Spectrum of Characteristics of Type 2 Diabetes: An International Real-World Analysis

PURPOSE: To extend a prior real-world analysis (DARWIN-T2D) of patients with type 2 diabetes initiating dapagliflozin in Italy, Greece, and Spain by evaluating changes in glycemic and extra-glycemic endpoints after initiation of dapagliflozin. PATIENTS AND METHODS: The association among demographic/...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fadini, Gian Paolo, Morales, Cristobal, Caballero, Irene, González, Beatriz, Tentolouris, Nikolaos, Consoli, Agostino
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9675331/ https://www.ncbi.nlm.nih.gov/pubmed/36411790 http://dx.doi.org/10.2147/DMSO.S390075

Ejemplares similares

A Multinational Real-World Study on the Clinical Characteristics of Patients with Type 2 Diabetes Initiating Dapagliflozin in Southern Europe
por: Fadini, Gian Paolo, et al.
Publicado: (2019)

Use and effectiveness of dapagliflozin in routine clinical practice: An Italian multicentre retrospective study
por: Fadini, Gian Paolo, et al.
Publicado: (2018)

Effectiveness of dapagliflozin versus comparators on renal endpoints in the real world: A multicentre retrospective study
por: Fadini, Gian Paolo, et al.
Publicado: (2018)

IDegLira for the Real-World Treatment of Type 2 Diabetes in Italy: Protocol and Interim Results from the REX Observational Study
por: Fadini, Gian Paolo, et al.
Publicado: (2022)

Effectiveness and safety of dapagliflozin in real-life patients: data from the DAPA-RWE Spanish multicentre study
por: Morales, Cristóbal, et al.
Publicado: (2022)

Eligibility of Dapagliflozin and Empagliflozin in a Real-World Heart Failure Population
por: Håkansson, Erik, et al.
Publicado: (2021)

Short-term effectiveness of dapagliflozin versus DPP-4 inhibitors in elderly patients with type 2 diabetes: a multicentre retrospective study
por: Morieri, M. L., et al.
Publicado: (2023)

Challenges and opportunities in real‐world evidence on the renal effects of sodium‐glucose cotransporter‐2 inhibitors
por: Fadini, Gian Paolo, et al.
Publicado: (2021)

Delphi-Based Consensus on Treatment Intensification in Type 2 Diabetes Subjects Failing Basal Insulin Supported Oral Treatment: Focus on Basal Insulin + GLP-1 Receptor Agonist Combination Therapies
por: Fadini, Gian Paolo, et al.
Publicado: (2021)

Effects of the SGLT2 inhibitor dapagliflozin on cardiac function evaluated by impedance cardiography in patients with type 2 diabetes. Secondary analysis of a randomized placebo-controlled trial
por: Bonora, Benedetta Maria, et al.
Publicado: (2019)

Effect of Dapagliflozin in Combination with Lobeglitazone and Metformin in Korean Patients with Type 2 Diabetes in Real-World Clinical Practice
por: Seo, Da Hea, et al.
Publicado: (2022)

Cardio–renal–metabolic syndrome: clinical features and dapagliflozin eligibility in a real‐world heart failure cohort
por: Beles, Monika, et al.
Publicado: (2023)

Real world data from a multi-centre study on the effects of cilostazol on pain symptoms and walking distance in patients with peripheral arterial disease
por: Katsiki, Niki, et al.
Publicado: (2022)

Similar effectiveness of dapagliflozin and GLP‐1 receptor agonists concerning combined endpoints in routine clinical practice: A multicentre retrospective study
por: Fadini, Gian Paolo, et al.
Publicado: (2019)

The Real DAPSI: A Real-World Retrospective Study on Assessing the Efficacy and Safety of a Fixed-Dose Combination of Dapagliflozin and Sitagliptin in the Indian Population
por: Bhattacharjee, Rana, et al.
Publicado: (2023)

Switching “Real-World” Diabetes Patients to Degludec from Other Basal Insulins Provides Different Clinical Benefits According to Their Baseline Glycemic Control
por: Tentolouris, Nikolaos, et al.
Publicado: (2019)

Efficacy and Safety of Dapagliflozin in Patients With CKD Across Major Geographic Regions
por: Vart, Priya, et al.
Publicado: (2022)

High prevalence of Trichomonas gallinae in wild columbids across western and southern Europe
por: Marx, Melanie, et al.
Publicado: (2017)

Effects of the SGLT2 inhibitor dapagliflozin on HDL cholesterol, particle size, and cholesterol efflux capacity in patients with type 2 diabetes: a randomized placebo-controlled trial
por: Fadini, Gian Paolo, et al.
Publicado: (2017)

Evaluation of real-world mepolizumab use in severe asthma across Europe: the SHARP experience with privacy-preserving federated analysis
por: Kroes, Johannes A., et al.
Publicado: (2023)

Real-world EGFR testing practices for non-small-cell lung cancer by thoracic pathology laboratories across Europe
por: Hofman, P., et al.
Publicado: (2023)

Real-world experience with secukinumab in the entire axial spondyloarthritis spectrum
por: Sivera, Francisca, et al.
Publicado: (2023)

A Comparison of the Pharmacokinetics and Safety of Dapagliflozin Formate, an Ester Prodrug of Dapagliflozin, to Dapagliflozin Propanediol Monohydrate in Healthy Subjects
por: Kim, Hyun Chul, et al.
Publicado: (2023)

Transposition of cardiovascular outcome trial effects to the real-world population of patients with type 2 diabetes
por: Sciannameo, V., et al.
Publicado: (2021)

Medium- and Long-Term Effects of Dapagliflozin on Serum Uric Acid Level in Patients with Type 2 Diabetes: A Real-World Study
por: Wang, Shihan, et al.
Publicado: (2022)

Effect of Dapagliflozin on Clinical Outcome after Drug-Eluting Stent Implantation in Elderly T2DM Patients: A Real-World Study
por: Lin, Yuan, et al.
Publicado: (2023)

Cost-effectiveness analysis of dapagliflozin for the treatment of type 2 diabetes mellitus in Spain: results of the DECLARE-TIMI 58 study
por: Escobar, Carlos, et al.
Publicado: (2022)

Influence of chronic kidney disease and its severity on the efficacy of semaglutide in type 2 diabetes patients: a multicenter real-world study
por: García de Lucas, María Dolores, et al.
Publicado: (2023)

Post-Authorization Safety Study of Hospitalization for Acute Kidney Injury in Patients with Type 2 Diabetes Exposed to Dapagliflozin in a Real-World Setting
por: Johannes, Catherine B., et al.
Publicado: (2022)

Effect of Dapagliflozin on Cause-Specific Mortality in Patients With Heart Failure Across the Spectrum of Ejection Fraction: A Participant-Level Pooled Analysis of DAPA-HF and DELIVER
por: Desai, Akshay S., et al.
Publicado: (2022)

Data on cost-optimal Nearly Zero Energy Buildings (NZEBs) across Europe
por: D'Agostino, Delia, et al.
Publicado: (2018)

Current Role of SLGT2 Inhibitors in the Management of the Whole Spectrum of Heart Failure: Focus on Dapagliflozin
por: Escobar, Carlos, et al.
Publicado: (2023)

Characteristics of Dapagliflozin Responders: A Longitudinal, Prospective, Nationwide Dapagliflozin Surveillance Study in Korea
por: Han, Eugene, et al.
Publicado: (2018)

The Outcomes of Dapagliflozin Use in Real-Life Clinical Settings in Endocrinology Clinics of Islamabad, Pakistan
por: Kamin, Matiullah, et al.
Publicado: (2020)

Real-World Treatment Patterns in Metastatic Castration-Resistant Prostate Cancer Across Europe (France, Germany, Italy, Spain, and the United Kingdom) and Japan
por: Leith, Andrea, et al.
Publicado: (2022)

Assessment of Glucose Lowering Medications’ Effectiveness for Cardiovascular Clinical Risk Management of Real-World Patients with Type 2 Diabetes: Targeted Maximum Likelihood Estimation under Model Misspecification and Missing Outcomes
por: Sciannameo, Veronica, et al.
Publicado: (2022)

Old world versus new world: life-history alterations in a successful invader introduced across Europe
por: Fox, Michael G., et al.
Publicado: (2013)

Surveying immigrants in Southern Europe: Spanish and Italian strategies in comparative perspective
por: Serrano Sanguilinda, Inmaculada, et al.
Publicado: (2017)

Real‐World Data for Regulatory Decision Making: Challenges and Possible Solutions for Europe
por: Cave, Alison, et al.
Publicado: (2019)

Lockdowns across Europe
por: Le Page, Michael
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_bnnegvdm1be7rflnt9hkilt3gr